NORTHLEAF-CAPITAL
Northleaf Capital Partners (Northleaf) is pleased to announce that funds managed by Northleaf have acquired a 90% stake in Douglas Terminals from Hartree Partners (UK) Limited (Hartree) and Ghent Transport & Storage NV (GTS).
Douglas Terminals is a 557,000-cubic metre liquid bulk storage terminal based in the Port of Ghent, Belgium. The facility consists of 17 high-quality tanks currently used for the storage of jet fuel, gasoil, diesel and biodiesel. Hartree and GTS started commercial operations at the terminal in 2017. GTS will retain a 10% stake and continue to operate the terminal under a management services agreement. As part of the transaction, Hartree, GTS and Northleaf have agreed to jointly develop Max Terminals, a new liquid storage terminal to be located on land adjacent to the Douglas Terminals site.
“Direct investments in high-quality bulk liquid storage assets are consistent with Northleaf’s strategy and offer our investors significant potential for stable, long-term returns,” said Roderick Gadsby, Managing Director at Northleaf. “This investment further strengthens and diversifies Northleaf’s portfolio of bulk liquid storage assets that now includes investments in the United States, United Kingdom, Belgium, Australia and New Zealand.”
“We are delighted to announce this transaction and are confident that Northleaf is the right majority owner of Douglas Terminals, given its experience in the liquid storage sector,” said Heiko Voelker, Director at Hartree. “We look forward to partnering with Northleaf on the development of Max Terminals in the future.”
“We have found our ideal long-term partner in Northleaf and are pleased that it supports Douglas Terminals’ strategy going forward,” said Yves Bienfet, Owner at GTS. “We are eager to work together with them in relation to Douglas Terminals, the development of Max Terminals and future opportunities in liquid storage.”
About Northleaf Capital Partners
Northleaf Capital Partners is an independent global private markets investment firm with more than US$13 billion in private equity, private credit and infrastructure commitments under management on behalf of public, corporate and multi-employer pension plans, endowments, foundations, financial institutions and family offices. Northleaf’s 140-person team, located in Toronto, Montreal, London, New York, Chicago, Menlo Park and Melbourne, is focused exclusively on sourcing, evaluating and managing private markets investments globally. Northleaf’s portfolio includes more than 350 active investments in 34 countries, with a focus on mid-market companies and assets. Northleaf currently manages seven global private equity funds, two specialist global private equity secondaries funds, three global private credit funds, three direct OECD-focused infrastructure funds and a series of customized investment mandates tailored to meet the specific needs of institutional investors and family offices. For more information on Northleaf, please visit www.northleafcapital.com .
About Hartree Partners (UK) Limited
Hartree Partners is a global merchant commodities firm specializing in energy, commodities and their associated industries. Formed in 1997, the firm now has over 10 offices around the world. The firm focuses on identifying value in the production, refinement, transportation and consumption of tradable commodities, and anticipating opportunities in the supply chain. Hartree Partners’ trading, investment and fund management arms are especially active in the energy and metals markets as well as the growing carbon and emissions markets.
About Ghent Transport & Storage NV
GTS is a family-owned business that specialises in the handling of bulk cargo. It operates three dedicated terminals in the Port of Ghent. It provides a wide range of port related services including bulk- and liquid storage, warehousing and freight forwarding.
Advisers
ABN AMRO acted as exclusive financial adviser to Hartree Partners and GTS, with Lydian acting as legal adviser.
Macquarie Capital acted as exclusive financial adviser to Northleaf Capital Partners, with Ashurst acting as legal adviser.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005241/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
Textron Aviation Defense Secures First Contract to Deliver Beechcraft T-6 Texan II Integrated Training System to Japan22.12.2025 02:00:00 CET | Press release
Textron Aviation Defense LLC, a Textron Inc. (NYSE:TXT) company, today announced that the company has finalized its first contract to deliver the Beechcraft T-6JP Texan II integrated training system to Japan’s Air Self-Defense Force (JASDF), in coordination with Kanematsu Corporation. The initial contract includes two Beechcraft T-6JP Texan II aircraft and instructor pilot and aircraft maintainer training materials. Deliveries of the first two aircraft are scheduled for 2029, with additional contracts anticipated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221925354/en/ The Beechcraft T-6 Texan II is designed and manufactured by Textron Aviation Defense LLC, a wholly owned subsidiary of Textron Aviation Inc. “This contract marks a pivotal step in strengthening Japan’s next-generation pilot training capabilities,” said Travis Tyler, president and CEO, Textron Aviation Defense. “We’re honored to support the Japan Air Se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom